The estimated Net Worth of Michael W. Nall is at least $1.24 millió dollars as of 19 October 2016. Mr. Nall owns over 36,363 units of Biocept Inc stock worth over $21,560 and over the last 10 years he sold BIOC stock worth over $0. In addition, he makes $1,216,060 as President, Chief Executive Officer és Director at Biocept Inc.
Sign up
Mr. Nall BIOC stock SEC Form 4 insiders trading
Michael has made over 2 trades of the Biocept Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 36,363 units of BIOC stock worth $39,999 on 19 October 2016.
The largest trade he's ever made was buying 36,363 units of Biocept Inc stock on 19 October 2016 worth over $39,999. On average, Michael trades about 3,720 units every 47 days since 2014. As of 19 October 2016 he still owns at least 49,575 units of Biocept Inc stock.
You can see the complete history of Mr. Nall stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Michael Nall biography
Michael W. Nall serves as President, Chief Executive Officer, Director of the Company. Mr. Nall has over 30 years of healthcare sales and marketing experience, serving as our CEO and President since 2013. Before joining Biocept, Mr. Nall served at Clarient Diagnostic Services, Inc. in positions of increasing responsibility from 2002 through August 2013, with his last position being General Manager, North American Sales and Marketing. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010. From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems. Mr. Nall received a Bachelor of Science degree in Business Administration from Central Missouri State University (now known as the University of Central Missouri). We selected Mr. Nall to serve on our board of directors due to his experience in the cancer diagnostics business, his expertise in the commercialization of products and services such as ours, his background in reimbursement and operations and his status as our chief executive officer and president.
What is the salary of Michael Nall?
As the President, Chief Executive Officer és Director of Biocept Inc, the total compensation of Michael Nall at Biocept Inc is $1,216,060. There are no executives at Biocept Inc getting paid more.
How old is Michael Nall?
Michael Nall is 57, he's been the President, Chief Executive Officer és Director of Biocept Inc since 2013. There are 16 older and 3 younger executives at Biocept Inc. The oldest executive at Biocept Inc is Margaret Faye Wilson, 82, who is the Lead Independent Director.
What's Michael Nall's mailing address?
Michael's mailing address filed with the SEC is C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO, CA, 92121.
Insiders trading at Biocept Inc
Over the last 11 years, insiders at Biocept Inc have traded over $2,456 worth of Biocept Inc stock and bought 1,703,300 units worth $1,869,312 . The most active insiders traders include Claire Reiss, Edward A. Neff és David F Hale. On average, Biocept Inc executives and independent directors trade stock every 92 days with the average trade being worth of $27,462. The most recent stock trade was executed by David F Hale on 9 December 2021, trading 445 units of BIOC stock currently worth $1,807.
What does Biocept Inc do?
biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar
What does Biocept Inc's logo look like?
Complete history of Mr. Nall stock trades at Biocept Inc
Biocept Inc executives and stock owners
Biocept Inc executives and other stock owners filed with the SEC include:
-
Michael Nall,
President, Chief Executive Officer, Director -
Timothy Kennedy,
Chief Financial Officer, Senior Vice President - Operations, Corporate Secretary -
Michael Terry,
Sr. VP of Corp. Devel. -
Lyle Arnold,
Senior Vice President - Research & Development, Chief Scientific Officer -
David Hale,
Non-Executive Chairman of the Board -
Samuel D. Riccitelli,
Interim Pres & CEO and Independent Chairman -
Margaret Faye Wilson,
Lead Independent Director -
Ivor Royston,
Independent Director -
Bruce Huebner,
Independent Director -
Bruce Gerhardt,
Independent Director -
Marsha Chandler,
Independent Director -
Samuel Riccitelli,
Director -
Michael Terry,
Senior Vice President - Corporate Development -
Cory Dunn,
Senior Vice President of Commercial Operations -
Antonio Paternostro,
VP of Sales -
Dr. Philippe J. Marchand Ph.D.,
Chief Operating Officer -
Dr. Michael C. Dugan M.D.,
Sr. VP, Chief Medical Officer & Medical Director -
Dr. Veena M. Singh,
Sr. Medical Director -
David S. Moskowitz R.Ph., MBA,
VP of Strategy & Corp. Communications -
Darrell Taylor Esq.,
Sr. VP, Chief Legal Officer & Chief Compliance Officer -
Dr. Lyle J. Arnold Ph.D.,
Chief Scientist & Member of Scientific Advisory Board -
Pavel Tsinberg,
Director of Technology Devel. -
Antonino Morales,
Interim CFO & Director -
Dr. Soon Kap Hahn Ph.D.,
Founder -
Quyen Thi Dao Haddock,
Director -
Bridge Lb Healthcare Master...,
-
Edward A. Neff,
Director -
Veena Singh,
Sr VP & Sr Med Director -
Claire Reiss,
10% owner -
Linda M Rubinstein,
Director -
Raaj Trivedi,
VP, COMMERCIAL OPERATIONS -
Mark G Foletta,
Interim CFO -
Philippe Marchand,
Chief Operations Officer -
William G Kachioff,
SVP, CFO AND SECRETARY -
Farideh Z. Bischoff,
VICE PRESIDENT -
Darrell Taylor,
See remarks -
Michael C Dugan,
Chief Med Off & Med. Director -
Antonino Morales,
Interim CFO